MiMark diagnostics

🌟 Our News from Chicago! 🌟 Before the summer break, the MiMARK team has traveled to Chicago to attend both the #ADLM2024 (formerly known as AACC) and the #DxPx US Investor & Industry Partnering Conference in Chicago! Our dynamic duo, Marina Rigau  and Cristina Vilarmau Marsinyach are on the ground, eager to dive into the latest advancements in diagnostics. At ADLM, we'll explore groundbreaking innovations in clinical laboratory science, network with industry leaders, and discover new technologies shaping diagnostics' future, like us! At the DxPx Conference, we look forward to strategic partnering opportunities, investor meetings, and collaborations that drive innovation in the Diagnostics sector. This is our first time attending these prestigious events, and we can't wait to learn, connect, and innovate! We are excited to engage with fellow professionals and forge new partnerships. If you're attending, let's connect and meet! 👉 ADLM Meeting 👉 DxPx Conference #MiMark #ADLM2024 #DxPx2024 #Diagnostics #Innovation #Healthcare #Networking #Chicago #MedicalConference #Partnerships

➡ Do you prefer the mountains or the beach?   After countless lunchtime debates about our dream getaways, it's finally time to make those plans a reality! Most of our team is taking a short break this summer to enjoy a well-deserved rest. We’re excited to recharge and come back with fresh ideas and renewed energy. Wishing everyone a fantastic summer break, filled with relaxation and fun! See you all soon, we will be back ready to tackle new challenges. 🌞🏖️🏔️ #SummerBreak #TeamRest #Recharge #MiMARK

🌿 What a fantastic day at Zizinia de les Flors! Yesterday, the MiMark team stepped out of the office and into the world of #fermentation. 🥣 From hands-on activities in making our own fermented products to enjoying a meal prepared right at Zizinia, we not only learned about the fermentation process but also about the importance of patience and precision—qualities that resonate deeply with our work in diagnostics. 🌱 At MiMark, we believe in nurturing our team’s growth both professionally and personally. Today was all about expanding horizons, exploring new skills, and continuing to cultivate a culture of continuous learning and well-being. A big thank you to Zizinia de les Flors for hosting us! #MiMark #TeamBuilding #EmployeeEngagement #ProfessionalDevelopment #FermentationWorkshop

🌟 Exciting News from MiMark! 🌟 We're honored to share that MiMARK has been selected as the winning solution at the #e_llasPitchDay. Marina Rigau (CEO) and Cristina Vilarmau Marsinyach (Innovation Manager) presented our approach based on the use of gynecological fluids to address endometrial cancer diagnosis, which resonated very well with the jury. The whole team’s hard work and dedication have been key to this recognition. We are looking forward to collaborating within the hub and GSK, and learning more as we develop our solution further. 🔗 Read more about the event and other participants here. We appreciate the support from the European Commission through the #HorizonEurope programme (HORIZON-EIC-2023-ACCELERATOR-01) for the support in the development of WomEC and everyone at the e-llas innovation hub. #HealthcareInnovation #WomenInTech #EndometrialCancer #MiMARK #WomEC #e_llas #EICAccelerator

🌟 Exciting News! 🌟 We are happy to announce the incorporation of Lola Fernández Encinas and Leandro Radusky into our team at MiMARK! Lola brings a wealth of experience in developing immunoassays for diagnostic purposes, Her incorporation will be instrumental in our efforts to validate WomEC, and also will provide support for our upcoming projects. Leandro has an impressive background in data science applied to the biomedical field, and his expertise in bioinformatics will be invaluable as we continue to grow and innovate. Welcome to the MiMARK family, Lola and Leandro! 🚀

June is Endometrial Cancer Awareness Month. Join us in raising awareness Endometrial cancer (EC) is a hot topic in research. It is the most common gynecological cancer in high-income countries, with an incidence projected to be a 46% higher by 2040. This makes it a pressing need to understand better the disease, and to find ways to treat and detect it early. During 2023, 90 studies related to EC were initiated. The studies ranged from evaluating new medications for treating EC to developing less invasive diagnostic methods for early detection. All the efforts shared a common concern: finding effective solutions for managing and overcoming EC. Patients who participate in these trials play a vital role, offering their time and health to advance knowledge and improve future care. Their trust drives research forward, making better treatments and simpler diagnostic methods available to the next generations. #EndometrialCancerAwareness #ECAwareness #WomensHealth #CancerDiagnosis #GynecologicalCancer #ECMonth #FightEC #Innovation #MiMARK

June is Endometrial Cancer Awareness Month. Join us in raising awareness What is the state of art of Endometrial Cancer? Endometrial cancer (EC) is a complex, heterogeneous condition. It's not just one disease but a family of disorders, each with varying severity and outcomes. Traditionally, EC was classified based on surgical findings, but today, molecular and genetic insights give us a deeper understanding.  The criteria for staging EC have recently been updated to include these insights, redefining the classification.  These advancements allow physicians to better understand the disease, obtaining a more accurate prognosis and better guiding the most effective treatments for each case. These findings mark a new era for innovation in diagnostics. With the discovery of biomarkers that can detect and stage EC with more precision, we enter a new era in personalized medicine. The hope is that these advancements will lead to earlier detection, more effective treatments, and improved outcomes for women diagnosed with EC. #EndometrialCancerAwareness #ECAwareness #WomensHealth #CancerDiagnosis #GynecologicalCancer #ECMonth #FightEC #Innovation #MiMARK

June is Endometrial Cancer Awareness Month. Join us in raising awareness At MiMARK we aim to avoid unnecessary diagnostic procedures for any women suspicious of having endometrial cancer (EC). How can science help us to achieve this goal? 🧑🏻🔬 Our body is full of proteins involved in countless processes that are essential for our daily life. Cancers such as EC, can create changes in the quantity of specific proteins that are critical for the progression of the tumor, thus leaving traces of the disease. These 'signature’ proteins, called biomarkers, can be used to diagnose cancer without the need for surgery, and are the basis of many innovative advances in diagnostic tests. At MiMARK, we have identified several of these proteins to detect EC, and we are developing a new diagnostic tool/test, WomEC, that will be able to detect and measure the quantity of these proteins to give a quick and accurate diagnosis to women. #EndometrialCancerAwareness #ECAwareness #WomensHealth #CancerDiagnosis #GynecologicalCancer #ECMonth #FightEC #Innovation #MiMARK

Hello there! Exciting news to finish the week with! Our Innovation Manager, Cristina Vilarmau Marsinyach, will be attending HLTH Europe in Amsterdam next week! ✨ We are so excited about this year's edition as HLTH Europe is putting a strong focus on Women’s Health through a dedicated Women’s Health program and area. And there is more! As part of the [w]Health community, Cristina will also participate in the [w]Health: Redesigning Healthcare with Women in Mind ideation workshop led by Kearney. It is an honor to be part of this initiative, and we are excited about the big things that will happen next week. Besides that, Cristina is looking forward to attending amazing talks focused on startup growth, women’s health challenges, investment, patient involvement, and reimbursement. She is also eager to meet potential partners and connect with others from the femtech community who share our goals. So, if you are attending HLTH Europe next week, do not hesitate to reach out and meet with us! Let’s work together to drive innovation and positive change in women's health! #HLTHEurope #WomensHealth #Innovation #Healthcare #Femtech #StartupGrowth #MiMARK #WHCommunity

June is #EndometrialCancerAwarenessMonth. Join us in raising awareness What is endometrial cancer? Endometrial cancer is the most common type of uterine cancer.   It origins in the endometrium, which is the inner lining of the utererine corpus.  Endometrial cancer is the most common gynecological cancer in high-income countries, with over 400,000 new cases annually. Dangerously, its incidence is increasing and projected to be a 46% higher by 2040 📈!This is probably due to the association of endometrial cancer with old-age and obesity, since these two risk factors are increasing in our society. Other risk factors of endometrial cancer are the exposure to high levels of estrogen, such as women having premature menstruation, late menopause, or tamoxifen intake, among others. Endometrial cancer occurs most commonly in women after menopause, being 60 years the average age of diagnosis. Only 2-14% of cases are diagnosed in women below 40 years old.   There are not screening tools for endometrial cancer. Importantly, women have to pay attention to symptoms in order to be diagnosed, and the main symptom is an abnormal uterine bleeding . Gynecologists encourage all women having this early sign to quickly seek for attention in order to have an early diagnosis of endometrial cancer. BUT, having abnormal vaginal bleeding is not equal of having cancer. Only 10% of women starting the diagnostic process will have cancer, whilst 90% of women will suffer unpleasant diagnostic procedures due to this unspecific symptomatology and lack of non-invasive diagnostics. #EndometrialCancerAwareness #ECAwareness #WomensHealth #CancerDiagnosis #GynecologicalCancer #ECMonth #FightEC #Innovation #MiMARK